TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06917742: A First-in-Human, Phase 1, Open-Label, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CPTX2309 by Intravenous Administration in Healthy Volunteers

Sponsor: Capstan Therapeutics · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 64 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,082,040

Rescue Site Savings

+$2,697,900

Unlock Full NCT06917742 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06917742 Rescue Dossier →